Akebia Therapeutics Expands Portfolio Beyond Anemia with New Rare Kidney Disease Pipeline Centered on AKB-097 and Praliciguat

Vafseo is an oral once-daily attraction for anemia owed to chronic kidney disease/CKD successful adults connected dialysis for astatine slightest 3 months and is not indicated arsenic a substitute for exigency humor transfusions. Vafseo is presently approved successful 37 countries and works by stimulating endogenous accumulation of erythropoietin. It carries a Boxed Warning regarding accrued risks of death, myocardial infarction, stroke, and vascular thrombosis.

Earlier connected November 28, Akebia entered into an Asset Purchase Agreement with Q32 Bio Inc. (NASDAQ:QTTB) to get the planetary rights to ADX-097, which is present renamed AKB-097. Akebia paid an upfront interest of $7 million, with an further $3 cardinal owed six months aft closing. AKB-097 is simply a humanized anti-C3d monoclonal antibody fusion macromolecule designed to people circumstantial sites of complement activation wrong tissues. Unlike systemic inhibitors, AKB-097 provides therapeutic levels of inhibition straight astatine the organ level, perchance reducing the hazard of corruption and the request for high-frequency dosing.

Akebia Therapeutics Inc. (NASDAQ:AKBA) is simply a biopharmaceutical institution that develops and commercializes therapeutics for patients with kidney diseases.

While we admit the imaginable of AKBA arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published at Insider Monkey.